AUG 26, 2021 8:00 AM PDT

Serum-free Expansion of NK Cells with K562- Based Feeder Systems for Clinical Applications

Speaker
  • Professor of Pediatrics and DiMarco Family Endowed Chair in Cell Based Therapy at Nationwide Children's Hospital
    BIOGRAPHY

Abstract
Date:  August 26, 2021
Time: 8:00am (PDT),  11:00am (EDT)
 
My translational research program focuses on approaches to enhance the natural killer (NK) cell response to cancer, with an emphasis on ex vivo expansion and engineering of NK cells to improve number and function for adoptive immunotherapy. Our K562-based feeder cell method results in consistent, robust expansion of highly-active clinical-grade NK cells that enables repeated delivery of large cell doses for improved efficacy. This finding led to several first-in-human clinical trials evaluating adoptive immunotherapy with expanded NK cells under FDA Investigational New Drug applications. We are now building on this platform to develop universal-donor NK cell approaches that further improve the efficiency and cost, particularly when applied to genetic and non-genetic methods for improved tumor targeting and tissue homing. Researchers face a variety of regulatory challenges when developing the manufacturing platform for NK cells at clinical grade and scale. We have previously grown clinical-grade NK cells with irradiated feeder cells and media containing human or bovine serum; however, these critical reagents carry inherent regulatory and medical risks. In this talk I will describe our results in testing and implementing a novel, GMP-manufactured NK cell-optimized medium that in combination with a xeno-free, GMP-manufactured serum replacement supports NK cell cultures to clinically relevant scale, which is superior to that of standard media with serum supplements and does not compromise NK cell activity or phenotype.
 
Learning Objectives
  • Discuss the potential of NK cells as applied to cell therapy in a clinical setting
  • Describe the relative tradeoffs associated with growing NK cells in feeder-dependent and feeder-free systems
  • Understand why NK cells can be superior to T cells for allogeneic solid tumor therapy development.
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
 

Show Resources
You May Also Like
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
JUN 03, 2021 12:00 PM CST
JUN 03, 2021 12:00 PM CST
DATE: June 3, 2021 TIME: 12:00pm SGT This webinar is a virtual event that focuses on utilizing the Gibco CTS Rotea System for Cell and Gene Therapy...
MAR 30, 2021 8:00 AM PDT
MAR 30, 2021 8:00 AM PDT
DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
Loading Comments...
Show Resources